diff --git a/figures/mouse_dosing_ivis.svg b/figures/mouse_dosing_ivis.svg
index 750d84b..e5eac79 100644
--- a/figures/mouse_dosing_ivis.svg
+++ b/figures/mouse_dosing_ivis.svg
@@ -1000,6 +1000,18 @@
id="path1058"
d="M 361.85937,636 H 410 v 73 h -48.14063 z m 0,0" />
+
+
+
+ inkscape:pagecheckerboard="0"
+ inkscape:snap-grids="false">
+ transform="matrix(0.67842202,0,0,0.67842202,-15.067948,-101.23376)">
-
-
-
-
-
-
-
-
-
-
-
-
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
-
-
-
-
-
-
-
-
-
- 0
- 20
- 40
- 60
- 80
- 100
-
-
-
-
-
-
-
-
-
-
- Days elapsed
-
-
- Percent survival
-
- Untreated
-
-
- Bead MedDose
-
-
-
- Bead LoDose
-
-
-
- Bead HiDose
-
-
-
- DMS HiDose
-
-
-
- DMS MedDose
-
-
-
- DMS LoDose
-
-
-
-
-
- **
- Bead
- Untreated
- DMS
-
-
-
-
- **
-
-
-
-
- **
-
-
-
-
- *
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
+ id="tspan107620" />
b.
+ y="277.97845">b.
c.
+ x="281.20248"
+ y="277.97845">c.
d.
+ x="0.61781627"
+ y="443.32932">d.
e.
+
+
+
+
+
+
+
+
+
+
+
+
+
+ 15
+ 20
+ 25
+ 30
+ 35
+ 40
+ 45
+ 50
+
+
+
+
+
+
+
+
+
+ 0
+ 20
+ 40
+ 60
+ 80
+ 100
+
+
+
+
+
+
+
+
+
+
+ Days elapsed
+
+
+ Percent survival
+
+ Untreated
+
+
+ Bead MedDose
+
+
+
+ Bead LoDose
+
+
+
+ Bead HiDose
+
+
+
+ DMS HiDose
+
+
+
+ DMS MedDose
+
+
+
+ DMS LoDose
+
+
+
+
+
+ **
+ Bead
+ Untreated
+ DMS
+
+
+
+
+ **
+
+
+
+
+ **
+
+
+
+
+ *
+
+
+
+ Survial
+ y="425.57568"
+ id="text121981">Survial
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ Survival (Bead High or Med vs DMS Lo)
+
Survival (Bead High or Med vs DMS Lo)
+ id="tspan121983-6"
+ x="357.25656"
+ y="451.4642">Survival (up to day 46)
+
diff --git a/tex/thesis.tex b/tex/thesis.tex
index 4873e30..b478e89 100644
--- a/tex/thesis.tex
+++ b/tex/thesis.tex
@@ -1960,15 +1960,16 @@ of both the bead medium dose and the bead high dose
of Nalm-6 tumor bearing \gls{nsg} mice shown in the
\cref{fig:mouse_dosing_ivis_survival} was up to day 40 as reported
elsewhere\cite{Fraietta2018}. However, we also included a Kaplan-Meier figure up
-to day 46 (Supplemental Figure 7) where most of the mice euthanized from day 40
-through day 46 from \gls{dms} groups showed no or very small fragment of spleen
-which was due to \gls{gvhd} responses. Similar \gls{gvhd} responses were
-reported earlier in \gls{nsg} mice where the mice injected with human \gls{pbmc}
-exhibited acute \gls{gvhd} between \SIrange{40}{50}{\day} post intravenous
-injection\cite{Ali2012}. Notably, both survival analyses (up to day 40 in
-\cref{fig:mouse_dosing_ivis_survival} and up to day 46 in Supplemental Figure 7)
-confirmed that \gls{dms}-expanded groups outperformed bead-expanded groups in
-terms of prolonging survival of Nalm-6 tumor challenged \gls{nsg} mice.
+to day 46 (\cref{fig:mouse_dosing_ivis_survival_full}) where most of the mice
+euthanized from day 40 through day 46 from \gls{dms} groups showed no or very
+small fragment of spleen which was due to \gls{gvhd} responses. Similar
+\gls{gvhd} responses were reported earlier in \gls{nsg} mice where the mice
+injected with human \gls{pbmc} exhibited acute \gls{gvhd} between
+\SIrange{40}{50}{\day} post intravenous injection\cite{Ali2012}. Notably, both
+survival analyses (up to day 40 in \cref{fig:mouse_dosing_ivis_survival} and up
+to day 46 in \cref{fig:mouse_dosing_ivis_survival_full}) confirmed that
+\gls{dms}-expanded groups outperformed bead-expanded groups in terms of
+prolonging survival of Nalm-6 tumor challenged \gls{nsg} mice.
Together, these data suggested that \glspl{dms} produce T cells that are not
only more potent that bead-expanded T cells (even when accounting for
@@ -2026,6 +2027,7 @@ cells are effective at lower doses.
\phantomsubcaption\label{fig:mouse_dosing_ivis_plots}
\phantomsubcaption\label{fig:mouse_dosing_ivis_survival}
\phantomsubcaption\label{fig:mouse_dosing_ivis_survival_comp}
+ \phantomsubcaption\label{fig:mouse_dosing_ivis_survival_full}
\endgroup
\caption[Mouse Dosing IVIS and Survival Results]
@@ -2038,6 +2040,9 @@ cells are effective at lower doses.
\subcap{fig:mouse_dosing_ivis_survival}{Survival plots of mice}
\subcap{fig:mouse_dosing_ivis_survival_comp}{Survival plots of mice showing
only those that received a comparable number of \gls{car} T cells.}
+ \subcap{fig:mouse_dosing_ivis_survival_full}{The same data as
+ \subref{fig:mouse_dosing_ivis_survival} except showing the full time until
+ euthanasia for all mice (including those that died via \gls{gvhd}).}
}
\label{fig:mouse_dosing_ivis}
\end{figure*}